Last Updated on October 9, 2024 by The Health Master
Bengaluru: The US Food and Drug Administration (USFDA) has approved Pfizer Inc’s next-generation vaccine to prevent pneumococcal disease in children aged six weeks to 17 years, the company said late on Thursday.
The vaccine, Prevnar 20, offers more protection against the disease versus the company’s widely-used Prevnar 13 vaccine, by targeting seven more serotypes of the streptococcus pneumoniae bacteria that causes those infections.
The pneumococcal disease can lead to infections in several parts of the body including the lungs, where they can cause pneumonia.
Prevnar 20 has also been approved to prevent a type of ear infection known as otitis media in infants six weeks through five years of age, the company said.
Advt The approval is based on results from mid-stage and late-stage studies that showed the vaccine’s safety and tolerability was similar to Prevnar 13.
About 2,000 cases of the disease occur each year in children under 5 years of age in the United States, according to the Center for Disease Control and Prevention.
USFDA gives approval for this ALS drug
USFDA gives nod for Nitrofurantoin Oral Suspension USP
USFDA gives approval for Icosapent Ethyl Capsules
USFDA gives approval for Metoprolol Tartrate tablet
USFDA gives approval for Roflumilast Tablets 250 mcg
USFDA gives nod for Azithromycin, used in bacterial infections
USFDA gives approval for this ALS drug
Relabeling of drug prices based on recent price changes in NLEM products
Drug recall: Thyronorm tablets recalled due to this reason
Govt likely to announce National Medical Device Policy
UK MHRA gives marketing authorisation for Cisplatin
Drug alert: 48 out of 1497 samples declared as NSQ in March 2023
Drug recall: Sun Pharma, Hetero recall these drugs
Medical Device alert: USFDA identifies recall of this Medical Device as most serious
Wet Granulation vs Dry Granulation: Understanding the Key Differences
Understanding GMP, cGMP, and WHO-GMP
Calibration of Laboratory Instruments
